A Double-Blind, Randomized, Placebo-Controlled Phase IIa Clinical Trial to Evaluate the Safety and Efficacy of DT2-SCT in Subjects With Type 2 Diabetes Mellitus

Prior treatment

• History of myocardial infarction or unstable angina in previous 3 months
• Subject who participated in another clinical trial within 6 months prior to the screening of this clinical trial
• Subject who was administered with immunosuppressants such as cyclosporin A or azathioprine within 6 weeks prior to the screening
• Subject is on chronic immunosuppressive transplant therapy
• Active cancer, chemotherapy, or other malignancies in the last 6 months prior to the screening
• Major surgeries within 6 months prior to the screening
• Wounds/sepsis ongoing or within 3 months prior to the screening

Other illness

• Subjects with Type 1 Diabetes Mellitus (T1DM) or secondary diabetes
• History of malignancy or current malignancy other than non-melanomatous skin cancer
• Subjects with active infections
• Subject with serious medical conditions other than cardiovascular disease
• Subject with, or with a medical history of auto-immune diseases
• Subject with a medical history of mental disorder or epilepsy
• Subject who was diagnosed with cancer within 5 years before screening
• Serious life-threatening conditions
• Allergies to anesthesia
• Subjects who tested positive for HIV 1/2, HBV, HCV, HTLV I/II, WNV, and syphilis
• Any past history of lipid disorders: lipedema, lipomatosis, or lipodystrophies
• Any past history of DVT or pulmonary embolism requiring anticoagulants or other medicines
• Any illness which in the Investigator's judgment, may interfere with the subject's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results

Lab values

• Subjects with serum creatinine 1.5 mg/dl or higher
• Abnormal liver function test (defined as value of transaminases \> 3 times the upper limit of normal or serum bilirubin higher than normal for the reference value for the laboratory)

Other

• Subject abuse alcohol 10 times a week or smoke 25 cigarettes a day
• Subject who is pregnant or nursing
• Flu symptoms
• Requiring supplemental oxygen

• Adults (male or female) between ages of 30 - 75 years
• Should have Type 2 diabetes mellitus
• With Insulin requirement of 0.7 IU/kg/d or 50 IU/d, whichever is lesser
• Glutamic acid decarboxylase (GAD) antibody status should be negative
• Body Mass Index (BMI) 19 - 30 kg/m2
• Fasting blood glucose (FBG) should be ≥ 7.0 mmol/L, and HbAc1 ≥ 7%
• Intravenous insulin tolerance tests (ITT) indicate a patient's insulin resistance
• Should be ambulatory and in good general health
• Willing and able to comply with the study procedures and visit schedules and able to follow verbal and written instructions
• Willing to abstain from the use of protocol-restricted treatments from Screening through the End-of-Treatment
• No clinically significant abnormalities observed in medical history, physical exam vital signs, and laboratory assessments
• For females with reproductive potential: Should agree to use effective contraception for at least 1 month prior to screening and should agree to use such a method till end of the study period and negative pregnancy test
• For males with reproductive potential: should use condoms and other methods to ensure effective contraception with a partner